{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:17:26Z","timestamp":1759961846419,"version":"3.32.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":7700,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1017\/s1041610203009633","type":"journal-article","created":{"date-parts":[[2004,4,14]],"date-time":"2004-04-14T15:06:12Z","timestamp":1081955172000},"page":"385-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer\u2019s Disease"],"prefix":"10.1016","volume":"15","author":[{"given":"Deborah","family":"Marin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Amaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Casciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine L.","family":"Puder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juuan","family":"Casciano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sobin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward H.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1017\/S1041610203009633_bb0005","unstructured":"Alzheimer\u2019s Association. (2002). Subsection: General statistics and demographics. Retrieved May 8, 2002, from http:\/\/www.alz.org"},{"key":"10.1017\/S1041610203009633_bb0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","article-title":"Projections of Alzheimer\u2019s disease in the United States and public health impact of delaying disease onset","volume":"88","author":"Brookmeyer","year":"1998","journal-title":"American Journal of Public Health"},{"key":"10.1017\/S1041610203009633_bb0015","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1212\/WNL.54.11.2072","article-title":"Age-specific incidence rates of Alzheimer\u2019s disease: The Baltimore Longitudinal Study of Aging","volume":"54","author":"Brookmeyer","year":"2000","journal-title":"Neurology"},{"key":"10.1017\/S1041610203009633_bb0020","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartarate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe AD","volume":"1","author":"Corey-Bloom","year":"1998","journal-title":"international Journal of Geriatric Psychopharmacology"},{"key":"10.1017\/S1041610203009633_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1","article-title":"The Caregiver Activity Survey (CAS): Development and validation of a new measure for caregivers of persons with Alzheimer\u2019s disease","volume":"12","author":"Davis","year":"1997","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1017\/S1041610203009633_bb0030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2307\/3350099","article-title":"Estimated prevalence of Alzheimer\u2019s disease in the US","volume":"68","author":"Evans","year":"1990","journal-title":"Milbank Quarterly"},{"key":"10.1017\/S1041610203009633_bb0035","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000008243","article-title":"A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe AD","volume":"44","author":"Farlow","year":"2000","journal-title":"European Neurology"},{"key":"10.1017\/S1041610203009633_bb0040","doi-asserted-by":"crossref","DOI":"10.2165\/00019053-199916020-00005","article-title":"Estimating long-term cost savings from treatment of Alzheimer\u2019s disease: A modeling approach","volume":"16","author":"Fenn","year":"1999","journal-title":"Pharmacoeconomics"},{"key":"10.1017\/S1041610203009633_bb0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1017\/S1041610200006499","article-title":"Impact of donepezil on caregiver burden for patients with Alzheimer\u2019s disease","volume":"12","author":"Fillit","year":"2000","journal-title":"International Psychogeriatrics"},{"key":"10.1017\/S1041610203009633_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"Journal of Psychiatric Research"},{"key":"10.1017\/S1041610203009633_bb0055","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00019053-200017040-00005","article-title":"Potential savings in the cost of caring for Alzheimer\u2019s disease: Treatment with rivastigmine","volume":"17","author":"Hauber","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1017\/S1041610203009633_bb0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1377\/hlthaff.17.6.206","article-title":"Alzheimer\u2019s disease care: Costs and potential savings","volume":"17","author":"Leon","year":"1998","journal-title":"Health Affairs (Millwood)"},{"year":"2000","series-title":"Impact of rivastigmine on costs and time spent caring for Alzheimer\u2019s disease patients","author":"Marin","key":"10.1017\/S1041610203009633_bb0065"},{"key":"10.1017\/S1041610203009633_bb0070","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"year":"2000","series-title":"Cost savings from decreased utilization of antipsychotic drugs associated with rivastigmine use in long-term care facilities [Abstract]","author":"Mends","key":"10.1017\/S1041610203009633_bb0075"},{"key":"10.1017\/S1041610203009633_bb0080","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1001\/jama.1996.03540210033030","article-title":"A family intervention to delay nursing home placement of patients with Alzheimer\u2019s disease: A randomized controlled trial","volume":"276","author":"Mittelman","year":"1996","journal-title":"Journal of the American Medical Association"},{"key":"10.1017\/S1041610203009633_bb0085","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1093\/geronb\/56.4.S219","article-title":"Informal costs of dementia care: Estimates from the National Longitudinal Caregiver Study","volume":"6B","author":"Moore","year":"2001","journal-title":"Journal of Gerontology"},{"key":"10.1017\/S1041610203009633_bb0090","series-title":"Family caregiving in the US: Findings from a national survey","first-page":"1","author":"National Alliance for Caregiving and American Association of Retired Persons","year":"1997"},{"key":"10.1017\/S1041610203009633_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1377\/hlthaff.12.2.164","article-title":"The economic burden of Alzheimer\u2019s disease care","volume":"12","author":"Rice","year":"1993","journal-title":"Health Affairs (Millwood)"},{"key":"10.1017\/S1041610203009633_bb0100","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with AD: International randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"British Medical Journal"},{"key":"10.1017\/S1041610203009633_bb0105","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1176\/ajp.143.11.1446","article-title":"Prevalence of mental illness in a community nursing home","volume":"143","author":"Rovner","year":"1986","journal-title":"American Journal of Psychiatry"},{"key":"10.1017\/S1041610203009633_bb0110","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.1997.03550160083043","article-title":"Diagnosis and treatment of Alzheimer\u2019s disease and related disorders: Consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer\u2019s Association, and the American Geriatrics Society","volume":"278","author":"Small","year":"1997","journal-title":"Journal of the American Medical Association"},{"key":"10.1017\/S1041610203009633_bb0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/136346159603300301","article-title":"Cross-cultural research on Alzheimer\u2019s disease: A critical review","volume":"33","author":"Smith","year":"1996","journal-title":"Transcultural Psychiatric Review"},{"year":"2002","series-title":"Montvale","author":"2002Red Book","key":"10.1017\/S1041610203009633_bb0120"},{"year":"1998","series-title":"Alzheimer\u2019s disease: Estimates of prevalence in the US (Publication GAO\/HEHS-98-16)","author":"U.S. General Accounting Office.","key":"10.1017\/S1041610203009633_bb0125"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224045198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1041610224045198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1041610203009633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T22:02:50Z","timestamp":1736373770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1041610224045198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S1041610224045198"],"URL":"https:\/\/doi.org\/10.1017\/s1041610203009633","relation":{},"ISSN":["1041-6102"],"issn-type":[{"type":"print","value":"1041-6102"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Rivastigmine on Costs and on Time Spent in Caregiving for Families of Patients With Alzheimer\u2019s Disease","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1017\/S1041610203009633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 International Psychogeriatric Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}